National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pomalidomide in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.

Rapid Review

Commenced Completed Outcome
20/09/2013 02/10/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
20/03/2014  10/03/2015 Reimbursement Not Recommended at the submitted price

Web Summary Pomalidomide (Imnovid)

December 2015

The HSE has approved reimbursement following confidential price negotiations.